Angina

Evolocumab ( Repatha ), a PCSK9 inhibitor, has shown to dramatically lower levels of low-density lipoprotein ( LDL), and also...


Results from the global phase III CANTOS study investigating the efficacy, safety and tolerability of Canakinumab ( ACZ885 )...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...


Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of...


Currently available antiarrhythmic agents for the treatment of atrial fibrillation have important limitations, leaving an unmet need for safe and...


A new analysis of the TECOS ( Trial Evaluating Cardiovascular Outcomes with Sitagliptin ) trial has shown that patients...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...


One-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the phase 2 ( OSLER-1 ) and phase 3...


Alirocumab ( Praluent ), a monoclonal antibody that inhibits proprotein convertase subtilisin – kexin type 9 ( PCSK9 ), has...


Data from the expansion phase of COSMIC-HF ( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure...


Merck, known as MSD outside the United States and Canada, issued the following statement after the conclusion of a meeting...



Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug Sitagliptin ( Januvia ) without an increased...


The immunosuppressant drug Cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention ( PCI...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and...


Currently available antiarrhythmic agents for the treatment of atrial fibrillation have important limitations, leaving an unmet need for safe and...


A study has assessed the effect of Ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial...


Researchers have investigated the risk for recurrent coronary events associated with insulin resistance in post infarction patients from the Thrombogenic...


A study has examined the efficacy and bleeding outcomes of Cangrelor ( Kengrexal ) in patients in the CHAMPION PHOENIX...


A study has estimated the frequency of cardiovascular events that occurred after diagnosis in a large Spanish cohort of patients...